Targeted delivery of siRNA to treat kidney damage after blood flow restoration
Official title: Tailored siRNA delivery to human endothelium to inhibit and reverse inflammatory damage following ischemia reperfusion injury in the kidney
Funded at Villanova University · NIH-11062052 · Data updated 2026-11-12
This study is looking at a new way to help protect kidneys from damage that can happen during organ transplants by using tiny particles to deliver special treatments directly to the kidney cells, with the goal of reducing inflammation and improving how the blood vessels work.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Villanova University NIH-funded |
| Lab location | 1 site (Villanova, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $58,434 |
| NIH project number | 3R00HL157552-05S1 |
| Project ID | NIH-11062052 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals undergoing kidney transplantation or those at risk of ischemia reperfusion injury.
✕Less likely to help
Patients with stable kidney function who are not undergoing transplantation or experiencing ischemia reperfusion injury may not benefit from this research.
What this research studies
This research focuses on developing a new treatment for kidney damage caused by ischemia reperfusion injury (IRI), which often occurs during organ transplants. The approach involves using specially designed nanoparticles to deliver small interfering RNA (siRNA) directly to endothelial cells in the kidneys, aiming to reduce inflammation and restore healthy blood vessel function. By targeting the specific cells affected by IRI, the researchers hope to improve kidney graft outcomes and overall organ health. The study will utilize advanced 3D models to evaluate the effectiveness of this targeted therapy in a controlled environment before testing in live models.
Why it matters
Potential benefit: If successful, this research could lead to improved kidney transplant outcomes and better management of kidney injuries caused by blood flow restoration.
How similar studies have gone: Previous research has shown promise in using targeted siRNA delivery for similar therapeutic approaches, indicating potential for success in this novel application.
Where this research is happening
-
Villanova University
Villanova, United States Active
Researchers
- Principal investigator: Bracaglia, Laura — Villanova University
- Study coordinator: Bracaglia, Laura
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.